Alejandro has worked with biotech and pharmaceutical companies since 2017, translating client needs into actionable, decision-driven insights. His engagements span early-stage drug development through pre-launch planning, with deep expertise in oncology, immuno-oncology, rare disease, and transplant.
More recently, he has pivoted into AI systems architecture and integration, embedding AI into commercial decision frameworks.
He holds a BS in Biology and a BA in Chemistry from Florida Institutional University, a PhD in Molecular and Cellular Biology from Institut Curie – Université Paris Descartes, and an MBA from UCSD.
Biotechnology companies face a critical inflection point when scientifically compelling results are no longer sufficient to carry the story and they must…
Read More